Beta-cell recovery to counter diabetesbroad
DiogenX · Horizon Europe grant · 2023-10-01–2025-09-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2023-ACCELERATOROPEN-01. CORDIS record →
Objective
Globally 8,75M people with T1D rely only on insulin administration to manage the symptoms of their disease. The treatment is complex since it requires injecting insulin (2-4 times/day) and adhering to a restrictive lifestyle (e.g., following a strict diet) reducing patient QoL. Even with insulin, less than 20% of patients achieve their target glucose level, which eventually leads to vascular complications (e.g., stroke, renal disease) reducing life expectancy by 10-15 years. DiogenX aims to withdraw insulin dependency and cure T1D by regenerating pancreatic beta-cell to allow autonomous insulin release in response to blood glucose levels increases.We expect to out-license our drug to a pharma company, some of them have already manifested their interest and invested in the capital of DiogenX. This may materialize as soon as clinical proof of principle is demonstrated in humans, which will be reached in 2026 with the proceeds from Series A to be raised in 2023, which is 80% secured.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| DIOGENX SAS | FR | coordinator | €2,500,000 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.